PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
25046055-8	2014	CONCLUSION: This study revealed that adding the mitiglinide/voglibose combination to a DPP-4 inhibitor elicited additive improvements in postprandial glycemic/metabolic responses assessed using MTTs at breakfast, lunch and dinner with identical meal compositions.	mitiglinide	48-59	dipeptidyl peptidase 4	Homo sapiens	87-92	
25810423-4	2015	Recently, it has been reported that the combination therapy of mitiglinide with a DPP-4 inhibitor could improve glycemic control.	mitiglinide	63-74	dipeptidyl peptidase 4	Homo sapiens	82-87	
24488695-9	2014	Following the addition of mitiglinide to the treatment regimen for 52 weeks, the early postprandial decrease in insulin secretion improved and PPG improved in both the DPP-4 inhibitor CTG and biguanide CTG.	mitiglinide	26-37	dipeptidyl peptidase 4	Homo sapiens	168-173	
24488695-0	2014	Long-term Effects of Mitiglinide in Japanese Diabetics Inadequately Controlled with DPP-4 Inhibitor or Biguanide Monotherapy.	mitiglinide	21-32	dipeptidyl peptidase 4	Homo sapiens	84-89	
24488695-3	2014	The aim of this study was to investigate the long-term efficacy and safety of mitiglinide in Japanese type 2 diabetic patients inadequately controlled by dipeptidyl peptidase-4 (DPP-4) inhibitor or biguanide monotherapy.	mitiglinide	78-89	dipeptidyl peptidase 4	Homo sapiens	154-176